Sleeping in low light can reverse DME changes

Article

Patients sleeping in a low-lit room may find that the changes in diabetic macular oedema (DME) are reversed.

Patients sleeping in a low-lit room may find that the changes in diabetic macular oedema (DME) are reversed, claims a study in Eye.

Dr G.B. Arden et al., School of Community and Health Sciences, City University, London, UK, conducted an investigation on 40 patients with mild non-proliferative diabetic retinopathy (DR) and early, untreated non-sight threatening DME. For six months all patients slept with a mask that illuminated the eyelid of a single closed eye with a 505 nm light.

The exclusion criteria were the presence of any concomitant eye disease and the primary outcome was the change in OCT retinal thickness where oedema was present.

Of the 40 patients observed, 34 completed the investigation. For study and fellow eyes the mean baseline OCT macular cube thickness was equivalent. It was found that the study eyes presented with a greater thickness in the central subfield zone 1 compared to the fellow eyes.

Intraretinal cysts were found in 28 eyes, compared to 9 found in the fellow eyes. Only 19 study eyes presented with cysts at 6 months, whilst 20 fellow eyes had cysts. In study eyes the worst affected ETDRS zone and the central subfield zone 1 experienced a reduction in thickness by 12μm.

In study eyes visual acuity, achromatic contrast sensitivity and microperimetric thresholds improved and in the fellow eyes they deteriorated.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.